AMRN

Amarin Corporation plc

Fundamental data last updated:June 4, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

IE

Next Earnings Date

07/29/2026

Business Summary

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

 


Analyze AMRN on TradingView

VALUATION

P/E

-8.97

Market Cap ($M USD)

$299.90M

Forward P/E

76.32

PEG

0.68

PRICE TO SALES

1.40

PRICE TO BOOK

0.67

EV / EBITDA

-77.29

5-Year Average P/E

Free Cash Flow Yield

8.51%

DCF Value

$-20.54

Graham Number

N/A

Price to FCF

11.76

EV to FCF

6.84

Earnings Yield

-11.14%

FCF Yield

8.51%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$1.62

Next Year EPS Growth Estimate

$0.19

Next Year Revenue Growth Estimate

$23.41B

Return on Equity (ROE)

-7.34%

FREE CASH FLOW

Operating Margin

-17.38%

Debt-to-Equity

0.03

Piotroski F-Score

4

Altman Z-Score

-1.68

Return on Invested Capital (ROIC)

-8.01%

Current Ratio

3.48

Quick Ratio

2.46

Net Debt to EBITDA

55.60

Interest Coverage

0.00

Gross Profit margin

52.48%

FCF PER SHARE

$1.23

REVENUE PER SHARE

$10.33

Analyze AMRN on TradingView

Gainseekers Quantitative Analysis

Summary

Amarin Corporation’s valuation paints a stark picture of market skepticism. With a DCF value deeply negative and a Graham Number unavailable, the stock appears mispriced, especially given its Forward P/E of 79.21, suggesting high growth expectations. However, the negative Earnings Yield and Altman Z-score of -1.64 indicate significant financial distress and potential insolvency risk. The market seems to be pricing in a turnaround, but the numbers suggest caution.

AI Exposure / Tech Reliance

Operating in the biotechnology sector, Amarin is positioned to leverage AI for drug discovery and personalized medicine, enhancing its R&D efficiency. However, the rapid pace of technological change demands agility, which can be challenging for established firms. The company's ability to integrate AI into its operations will be crucial for maintaining competitiveness.

The Bull Case

For the value or GARP investor, Amarin offers intriguing prospects. The Forward PEG ratio of 0.71 indicates potential undervaluation relative to its growth, while a solid FCF Yield of 8.19% suggests efficient cash generation. Despite a negative ROIC, the company's strong current ratio of 3.48 and a Piotroski F-Score of 4 highlight reasonable financial health and operational efficiency. These metrics hint at underlying pricing power and capital efficiency that could appeal to discerning investors.

The Bear Case

Yet, the bear case is hard to ignore. Amarin's negative EPS and operating margin of -17.38% underscore a struggle to achieve profitability. The EV to EBITDA ratio of -82.33 signals severe operational challenges. Additionally, the stock's proximity to its 52-week high, coupled with a Price/Book ratio below 1, suggests that any missteps could lead to significant downside risk. The market's optimism may be premature given these structural weaknesses.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Hold

Average Analyst Price Target

$2.17

Institutional Ownership %

1-Year Beta

0.82

Insider Buying % (6 Mo)

Distance to 52-Week High

44.14%

Distance to 52-Week Low

22.28%

EARNINGS SURPRISE %

-1,000.00%

50-DAY SMA

$14.55

200-DAY SMA

$15.44

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.